Dose-finding Study Comparing Efficacy and Safety of a PARP Inhibitor Against Doxil in BRCA+ve Advanced Ovarian Cancer

Clinical trial NCT00628251 · COMPLETED

Trial details

NCT number: NCT00628251
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Ovarian Neoplasms

Start date: 2008-07-30
Primary completion: 2009-09-15
Enrollment: 97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.